E-LIB Suche - Ergebnisse für: Cañás Martín

1

A Cross-National Comparison of Biosimilars Pricing in Argen..:

da Silva Machado, Fernanda Lacerda ; Cañás, Martín ; Urtasun, Martín A....
Therapeutic Innovation & Regulatory Science. 58 (2024) 3 - p. 549-556 , 2024

Link: https://doi.org/10.1007/..

2

Meniscal Lesions in Multi-Ligament Knee Injuries:

Figueroa, David ; Figueroa, María Loreto ; Cañas, Martin..
Indian Journal of Orthopaedics. , 2024

Link: https://doi.org/10.1007/..

3

Biosimilars approvals by thirteen regulatory authorities: A..:

Machado, Fernanda Lacerda da Silva ; Cañás, Martín ; Doubova, Svetlana V....
Regulatory Toxicology and Pharmacology. 144 (2023) - p. 105485 , 2023

Link: https://doi.org/10.1016/..

4

La fijación con tornillo de interferencia tibial cuadrante ..:

Vaisman, Alex ; Cañas, Martin ; Ruiz, Asunción...
Revista Chilena de Ortopedia y Traumatología. 63 (2022) 1 - p. e9-e16 , 2022

Link: https://doi.org/10.1055/..

5

Medicamentos retirados en otros países por problemas de seg..:

Buschiazzo, Héctor ; Dorati, Cristian ; Iusef Venturini, Nasim...
Revista de la Facultad de Ciencias Médicas de Córdoba. 79 (2022) 3 - p. 241-247 , 2022

Link: https://doi.org/10.31053..

6

Data sources for drug utilization research in Latin America..:

Lopes, Luciane C. ; Salas, Maribel ; Osorio‐de‐Castro, Claudia Garcia Serpa...
Pharmacoepidemiology and Drug Safety. 31 (2022) 3 - p. 343-352 , 2022

Link: https://doi.org/10.1002/..

7

Consumo de benzodiazepinas y fármacos Z en una organización..:

Marin, Gustavo ; Del Mauro, Julieta ; Marin, Lupe...
Salud Colectiva. 17 (2021) - p. e3583 , 2021

Link: https://doi.org/10.18294..

8

Potential negative impact of reputed regulators' decisions ..:

Durán, Carlos E. ; Cañás, Martín ; Urtasun, Martín...
PLOS ONE. 16 (2021) 7 - p. e0254585 , 2021

Link: https://doi.org/10.1371/..

9

Reducción de la cobertura social para los fármacos antiartr..:

Urtasun, Martín A. ; Noble, María ; Cañás, Martín...
Salud Colectiva. 17 (2021) - p. e3246 , 2021

Link: https://doi.org/10.18294..

10

Data transparency for building a stronger healthcare system..:

Cañás, Martín ; Marín, Gustavo H. ; Urtasun, Martín A....
Salud Colectiva. 17 (2021) - p. e3339 , 2021

Link: https://doi.org/10.18294..

11

Valor terapéutico y precio de los nuevos fármacos comercial..:

Urtasun, Martín Alejandro ; Buschiazzo, Héctor Omar ; Cañás, Martín
Salud Colectiva. 15 (2019) - p. e1962 , 2019

Link: https://doi.org/10.18294..

12

EMA and FDA decisions based on flawed evidence to approve n..:

Durán, Carlos E ; Cañás, Martín ; Chistiaens, Thierry
BMJ: British Medical Journal. 367 (2019) - p. 1 ff. , 2019

Link: https://www.jstor.org/st..

13

P2‐576: UTILIZATION PATTERN AND COST ANALYSIS OF ANTI DEMEN..:

Demey, Ignacio ; Rojas, Galeno ; O'Neill, Santiago...
Alzheimer's & Dementia. 15 (2019) 7S_Part_16 - p. , 2019

Link: https://doi.org/10.1016/..

14

What is happening with not recommended drugs for dementia i..:

Bustin, Julian ; Rojas, Galeno ; O'Neill, Santiago...
International Journal of Geriatric Psychiatry. 35 (2019) 3 - p. 270-275 , 2019

Link: https://doi.org/10.1002/..

15

Comment on: "Coxibs Refocus Attention on the Cardiovascular..:

Urtasun, Martin A. ; Prozzi, Guillermo R. ; Marín, Gustavo H....
American Journal of Cardiovascular Drugs. 17 (2017) 6 - p. 493-495 , 2017

Link: https://doi.org/10.1007/..